Predictive value of micro-RNA expression profiling in pediatric desmoid fibromatosis

Figures & data

Figure 1. (A) patient outcomes according to treatment modality (B) extremity patients outcomes according to treatment modality.

Table 1. Differentially expressed miRNAs among unsupervised analysis (G1 and G2) and among supervised analysis (observation and extremity groups).

Differentially expressed miRNAs among unsupervised analysis (G1 and G2)
	miRNA	Regulation	Log 2-Fold Change	P-adjusted
	hsa-miR-1-3p	Downregulated	−3.4232809	0.00113696*
	hsa-miR-499a-5p	Downregulated	−3.3597613	0.02954173*
	hsa-miR-205-5p	Upregulated	6.70774762	0.00274664*
	hsa-miR-193a-5p	Upregulated	1.20718178	0.02954173*
	hsa-miR-320c	Upregulated	1.57412978	0.02954173*
	hsa-miR-10395-5p	Upregulated	2.32702366	0.03138039*
	hsa-miR-10395-3p	Upregulated	1.8979117	0.04199397*
Differentially expressed miRNAs among supervised analysis
Group	miRNA	Regulation	Log 2-Fold Change	P-adjusted
Observation	hsa-miR-378a-5p	Downregulation	−3.3	0.034*
	hsa-miR-133a-3p	Downregulation	−5.57	0.01*
Extremity	hsa-miR-378a-3p	Downregulation	−2.04	0.032*
	hsa-miR-1-3p	Downregulation	−2.75	0.007*
	hsa-miR-451a	Downregulation	−2.56	0.008*

*Statistically significant; miRNA: micro RNA; G1: unsupervised group 1; G2: unsupervised group 2; PD: Progressive/Recurrent; CR/PR/MR/SD: Complete response/Partial response/Minor response/Stable disease.

Figure 2. Box plot for the actual expression level for the five recommended miRNAs.

Data availability statement

Data used to support the findings of this study are available from the corresponding author upon request.

https://www.ncbi.nlm.nih.gov/bioproject/PRJNA890940.